Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

Clinical calculator summary

ESGO/ESTRO/ESP Endometrial Risk (2021)

The ESGO-ESTRO-ESP 2021 guidelines incorporate molecular classification (POLE, MMRd, p53) for risk stratification.

Evidence-based context for fast calculator use

Purpose:
ESMO 2021 Risk Classification stratifies endometrial cancer by stage, grade, and LVSI to guide adjuvant radiotherapy and chemotherapy decisions.
Population:
patients undergoing ovarian, cervical, endometrial, or gestational-trophoblastic risk and staging assessment
Factors:
FIGO Stage, Histological Type, Tumor Grade, Lymphovascular Space Invasion
Reference:
Concin N, Matias-Guiu X, Vergote I, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer. 2021;31(1):12-39.
HomeESGO/ESTRO/ESP Endometrial Risk (2021)
Pin your most used calculators here by clicking the star in the dropdown.

ESGO/ESTRO/ESP Endometrial Risk (2021)

Clinical Context & Background

The ESGO-ESTRO-ESP 2021 guidelines incorporate molecular classification (POLE, MMRd, p53) for risk stratification. This calculator approximates the consensus for patients where molecular classification is unknown/unavailable, relying on Stage, Grade, Histology, and LVSI. Note: "Substantial" LVSI significantly increases risk.
Primary Source EvidenceConcin N, Matias-Guiu X, Vergote I, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer. 2021;31(1):12-39.
Formula Logic
Classification based on Stage, Grade, Histology, and LVSI (Substantial vs Focal).

Reference Data

Risk Group (Molecular Unk)Typical Management
LowObservation
IntermediateBrachytherapy alone
High-IntermediateEBRT +/- Brachytherapy
HighEBRT + Chemotherapy

Clinical Workflow

Use, Interpret, And Continue The Patient Pathway

Expand for workflow guidance, limitations, examples, and related next steps.

When To Use

  • Use ESGO/ESTRO/ESP Endometrial Risk (2021) when eSMO 2021 Risk Classification stratifies endometrial cancer by stage, grade, and LVSI to guide adjuvant radiotherapy and chemotherapy decisions.
  • Confirm that the patient, diagnosis, disease phase, and available inputs match the cited model before calculation.

How To Interpret

  • Interpret the displayed result using the calculator-specific formula and reference table, spanning Low through High.
  • A boundary result should prompt input verification and clinical review rather than false precision.

What To Do Next

  • Confirm organ site, pathology, menopausal or postoperative context, imaging, biomarker assay, and specialist referral pathway.
  • Document the inputs, result, timing, and clinical context so the assessment can be reproduced.

Limitations

  • Adnexal-mass, cervical postoperative, endometrial, and ovarian cytoreduction models answer different clinical questions.
  • The result supports clinician judgment and does not independently determine treatment.

Validated Population

patients undergoing ovarian, cervical, endometrial, or gestational-trophoblastic risk and staging assessment

How to apply this result

For a representative case, verify FIGO Stage, Histological Type, Tumor Grade, calculate the result, and confirm that its classification matches the highlighted reference band before continuing the disease-specific pathway.

Gynecologic Oncology hubContinue to related calculators and clinical workflow resources.

Share This Calculator

Share:

Related Tools

FIGO GTN Risk ScoreRMI (Risk of Malignancy Index)ROMA Score (Ovarian)

Frequently Asked Questions

When should ESGO/ESTRO/ESP Endometrial Risk (2021) be used?

Use it for patients undergoing ovarian, cervical, endometrial, or gestational-trophoblastic risk and staging assessment when all required inputs and the intended clinical setting are confirmed.

Can ESGO/ESTRO/ESP Endometrial Risk (2021) determine treatment by itself?

No. Interpret the result with the cited evidence, complete clinical assessment, current guidelines, and patient-specific goals.

Evidence-based oncology decision support. Verify with clinical guidelines.